Phio Pharmaceuticals Corp.

Last updated September 27, 2026

Organization details

Legal name
Phio Pharmaceuticals Corp.
Former names
RXi Pharmaceuticals Corp
Ownership
Public
Status
Active
Sector (GICS)
Health Care
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Delaware
Headquarters city
King of Prussia
Headquarters state / province
Pennsylvania
Headquarters country
United States
Fiscal year end
December
Ticker symbol
PHIO
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001533040
EIN
45-3215903

Board of directors

Chief executives

Robert J. Bitterman · President & CEO
Dates unknown

Director election results

Annual meeting of September 28, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$136,990
16 purchases by 4 insiders
Sold, last 12 months
$0
0 sales by 0 insiders
Date Insider Transaction Shares Price Value
Nov 11, 2026 David H. Deming Director Open-market purchase +5,200 $0.84 $4,358
Nov 10, 2026 David H. Deming Director Open-market purchase +6,800 $0.84 $5,709
Nov 9, 2026 Robert J. Bitterman Director, Officer (Chairman, Pres. & CEO) Open-market purchase +25,000 $0.82 $20,500
Nov 9, 2026 Ronald Todd Plott Director Open-market purchase +18,300 $0.83 $15,189
Sep 29, 2026 Ronald Todd Plott Director Open-market purchase +5,000 $1.04 $5,200
Sep 28, 2026 Robert J. Bitterman Director, Officer (Chairman, Pres. & CEO) Grant or award +400,000 — —
Sep 28, 2026 Carson Lisa Cabott Officer (Chief Financial Officer) Grant or award +108,000 — —
Sep 28, 2026 Ronald Todd Plott Director Grant or award +17,000 — —
Sep 28, 2026 Ronald Todd Plott Director Open-market purchase +5,000 $1.03 $5,150
Sep 24, 2026 Patricia A. Bradford Director Open-market purchase +6,500 $1.01 $6,565
Sep 22, 2026 Robert J. Bitterman Director, Officer (Chairman, Pres. & CEO) Open-market purchase +2,000 $1.03 $2,060
Sep 15, 2026 Patricia A. Bradford Director Open-market purchase +12,000 $1.03 $12,360
Sep 11, 2026 Robert J. Bitterman Director, Officer (Chairman, Pres. & CEO) Shares withheld for tax −68,550 $1.03 $70,607
Sep 11, 2026 Carson Lisa Cabott Officer (Chief Financial Officer) Shares withheld for tax −12,888 $1.03 $13,275
Aug 19, 2026 Ronald Todd Plott Director Open-market purchase +15,000 $1.14 $17,100

Organizations in the same sector, closest in location and size first.

Questions about Phio Pharmaceuticals Corp.

Who is the CEO of Phio Pharmaceuticals Corp.?

Robert J. Bitterman is Phio Pharmaceuticals Corp.'s President & CEO.

How many directors are on Phio Pharmaceuticals Corp.'s board?

Phio Pharmaceuticals Corp.'s board has 8 directors: Curtis Lockshin, David H. Deming, Geert Cauwenbergh, Jonathan E. Freeman, Patricia A. Bradford, Robert J. Bitterman, Robert L. Ferrara and Ronald Todd Plott.

Are Phio Pharmaceuticals Corp. insiders buying or selling shares?

Over the last 12 months, Phio Pharmaceuticals Corp. insiders bought $136,990 of shares in 16 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="phio-pharmaceuticals-corp"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.